...
首页> 外文期刊>The Journal of biological chemistry >Phosphorylation and Stabilization of Topoisomerase IIα Protein by p38γ Mitogen-activated Protein Kinase Sensitize Breast Cancer Cells to Its Poisons
【24h】

Phosphorylation and Stabilization of Topoisomerase IIα Protein by p38γ Mitogen-activated Protein Kinase Sensitize Breast Cancer Cells to Its Poisons

机译:P38γ丝裂剂激活蛋白激酶对乳腺癌细胞敏化乳腺癌细胞乳腺癌细胞磷酸化和稳定化

获取原文

摘要

Cancer drugs suppress tumor cell growth by inhibiting specific cellular targets. However, most drugs also activate several cellular nonspecific stress pathways, and the implications of these off-target effects are mostly unknown. Here, we report that p38γ, but not p38α, MAPK is specifically activated by treatment of breast cancer cells with topoisomerase II (Topo II) drugs, whereas paclitaxel (Taxol) does not have this effect. The activated p38γ in turn phosphorylates and stabilizes Topo IIα protein, and this enhances the growth inhibition by Topo II drugs. Moreover, p38γ activity was shown to be necessary and sufficient for Topo IIα expression, the drug-p38γ-Topo IIα axis is only detected in intrinsically sensitive but not resistant cells, and p38γ is co-overexpressed with Topo IIα protein in primary breast cancers. These results reveal a new paradigm in which p38γ actively regulates the drug-Topo IIα signal transduction, and this may be exploited to increase the therapeutic activity of Topo II drugs.
机译:癌症药物通过抑制特异性细胞靶标抑制肿瘤细胞生长。然而,大多数药物也激活几种细胞非特异性应力途径,并且这些偏离目标效应的影响大多是未知的。在这里,我们报告了P​​38γ,但不是P38α,MAPK通过用TOPOISOMERASE II(TOPO II)药物治疗乳腺癌细胞来特异性激活,而PACLITAXEL(紫杉醇)没有这种效果。活化的P38γ反过来磷酸化并稳定TopoIIα蛋白,这提高了Topo II药物的生长抑制。此外,显示P38γ活性对于TopoIIα的表达是必要的并且足以足以在本质上敏感但不抗性细胞中检测到药物-P38γ-TopoIIα轴,并且P38γ在原代乳腺癌中与TopoIIα蛋白共同表达。这些结果揭示了一种新的范例,其中P38γ积极调节药物 - TopoIIα信号转导,并且可以利用这增加Topo II药物的治疗活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号